• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to footer
  • Subscribe
  • facebook
  • instagram
  • RSS
  • RSMUS.com

The Real Economy Blog

Search

  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences
Home > Coronavirus > 5 things to know this week in life sciences: Week of Dec. 21

5 things to know this week in life sciences: Week of Dec. 21

Dec. 23, 2020 by Steve Kemler and Adam Lohr

  • email
  • Twitter
  • Facebook
  • Linkedin

With approval of Moderna’s COVID-19 vaccine last week for emergency use, many of us are looking forward to getting vaccinated with the hope that it will help us return to a more normal life. While looking forward, this is also a good time to reflect on the decades of work that laid the groundwork for this lightning fast vaccine development effort, as the first article in our roundup does.

Additionally, we look at the types of companies that will be attractive M&A targets in the coming quarters and years, consider the continued exposure to cyberattacks for life sciences companies, and see another example of a company looking to move from injections to pills.

Each week, we highlight five things you need to know about in the life sciences industry. Here’s the latest.

mRNA vaccines have only been in the public eye for a few months – but the road to this point was long

This year, we have seen a tremendous sprint in vaccine development and trials for a disease that wasn’t even known at this point last year. We have seen the hope that these accomplishments have brought to the whole world. But we shouldn’t lose sight of the years of quiet toil in the lab, the setbacks, and the stories of the people in the life sciences industry that made this possible.

Moderna and BioNTech, for instance, started long ago down the path that made their recent COVID-19 vaccine achievements possible, and their work built on decades of scientific research around the possibilities of mRNA. The STAT article above tells the story.

The Pfizer/BioNTech and Moderna vaccines are both mRNA-based, but there are important differences

Sometime in the coming year, Americans will line up and get a shot in the arm with a COVID-19 vaccine. For most of us, it really won’t matter which of the vaccines we get; we will just be relieved to finally be getting one. For the life sciences industry, it is helpful to understand the similarities and differences and how those differences will impact production and distribution. This piece takes a look at those distinctions.

A glimpse at future medical device and medtech M&A targets

Fierce Biotech released a list of its top medtech M&A targets this week, and it is worth a read. The specific companies highlighted are interesting on their own, with their work in creating new sensors, deploying artificial intelligence in new ways, and leveraging the cloud to bring treatment to patients wherever they are. But these companies are also noteworthy because of their implications for other businesses, especially in the broader tech space.

Cyber risks grow with the industry’s increasing visibility

The critical work life sciences companies have done this year has raised the industry’s profile, and many benefits have accompanied that increased awareness. Unfortunately, such high-profile work continues to attract threat actors as well. 2021 looks to be the year when many life sciences companies will be forced to take cybersecurity more seriously, this article explains.

Myovant hopes to move beyond needles in treatments for prostate cancer

Last week, the FDA approved Myovant’s Orgovyx as an oral treatment for prostate cancer, a big advancement in treatments for the disease. Whereas existing treatments require injections or implants, patients can take this new therapy orally at home. Not only does this make the treatment more convenient, it’s a welcome change for those who prefer pills over needles. It also allows cancer patients with suppressed immune systems to avoid additional trips to clinics, which is a benefit in both pandemic years and normal years.

  • email
  • Twitter
  • Facebook
  • Linkedin

Related posts

  • 5 things to know this week in life sciences: Week of Dec. 14

    With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people…

  • 5 things to know this week in life sciences: Week of Dec. 7

    This is the first installment of a new weekly roundup in which we highlight five things you need to know about in the life sciences industry. Here’s the latest, including COVID-19 vaccine news, a deal between Palantir and…

  • Life science graphic
    Better data use has pros and cons for life sciences

    The volume and variety of health care data should expand significantly in 2019. Specifically, we will be monitoring growth in data sources outside those collected from traditional electronic health records, including information gleaned from wearable technology and direct-to-consumer…

Filed Under: Coronavirus, Life Sciences Tagged With: biotech, Covid-19, covid-19 vaccine, life sciences, moderna, pfizer, pharmaceuticals, vaccine

About Steve Kemler

Steve manages the Philadelphia market NetSuite team and provides NetSuite consulting services to a variety of clients in industries including life sciences, technology and wholesale distribution. Steve leads projects that require complex integrations, customizations and complex finance requirements.

As a member of RSM’s life sciences team, Steve consistently supports clients in the industry across the country. He also participates in the PACT MedTech series and is involved in multiple regional life sciences initiatives.

In May 2020, Steve was selected as a senior analyst in RSM’s cutting edge Industry Eminence Program, which positions its senior analysts to understand, forecast and communicate economic, business and technology trends shaping the industries RSM serves.

About Adam Lohr

Adam is an audit partner and life sciences senior analyst in RSM's cutting-edge industry eminence program. In addition to providing assurance services to his clients, he sits on RSM’s national life science team and leads the San Diego office life science practice.

His senior analyst responsibilities include advising the firm’s life sciences care clients and client servers as they work to navigate the rapidly changing industry environment. Adam regularly writes, presents and advises on capital markets, digital transformation, policy and other issues transforming life sciences. He is an instructor at the regional and national level, and is experienced in the application of ASC 606 revenue recognition for the technology and consumer products industries.

Adam has over 12 years of accounting and finance experience, serving private equity-backed and private closely held companies in the middle market. He specializes in providing financial audit services and helping clients respond to technical, regulatory and economic changes that impact their business.

Primary Sidebar

Read RSM analysts’ industry coverage of coronavirus.

Categories

  • Economics
  • Technology
  • Consumer Products
  • Industrials
  • Financial Services
  • Real Estate
  • Health Care
  • Life Sciences

Recent Life Science articles

5 things to know in life sciences: Week of Jan. 18

Jan. 21, 2021

5 things to know this week in life sciences: Week of Jan. 11

Jan. 15, 2021

This year may be the busiest ever for health care and life sciences deal volume

Jan. 12, 2021

RSMUS.com links

The Real Economy

Middle Market Business Index

MMBI Special Reports

Footer

  • Facebook
  • Instagram
  • RSS

About The Real Economy Blog

The Real Economy Blog from RSM US LLP was developed to provide timely economic insights about the middle market economy. It is offered as a complement to RSM’s macroeconomic thought leadership, including The Real Economy monthly publication and the proprietary RSM US Middle Market Business Index (MMBI).

© 2021 RSMUS.com | Privacy Policy | Cookie Policy

The Real Economy Blog
  • Economics
  • Technology
  • Consumer
  • Industrials
  • Finance
  • Real Estate
  • Health Care
  • Life Sciences